免疫抑制与免疫正常患者Mohs显微描记手术的前瞻性全国队列研究
基于西班牙REGESMOHS登记处7年前瞻性队列,纳入5226例接受Mohs显微描记手术的非黑素瘤皮肤癌患者,其中免疫抑制157例、免疫正常5069例。免疫抑制患者鳞状细胞癌比例更高、多发性同步肿瘤更多、肿瘤侵犯更深结构,复杂闭合、未完成Mohs及更多手术切片更常见,复发率显著更高(IRR 2.79)。
要点
- 免疫抑制患者Mohs术后复发风险显著升高(IRR 2.79),需密切随访。
- 免疫抑制患者鳞状细胞癌比例更高、多发性同步肿瘤更多、肿瘤侵犯更深。
- 免疫抑制患者复杂闭合、未完成Mohs及更多手术切片更常见。
核心结论
- 免疫抑制患者接受Mohs显微描记手术治疗非黑素瘤皮肤癌时,不良事件(如出血或肿瘤坏死)风险可能更高,肿瘤复发风险也更高。
- 密切随访并考虑免疫抑制患者非黑素瘤皮肤癌的特殊特征至关重要。
研究设计与样本
- 研究利用西班牙REGESMOHS登记处数据,为7年前瞻性队列研究。
- 共纳入5226例患者,分为免疫正常组5069例和免疫抑制组157例。
- 免疫抑制患者包括实体器官移植受者、接受免疫抑制治疗者、血液系统肿瘤患者和HIV阳性患者。
主要发现
- 免疫抑制患者鳞状细胞癌比例更高、多发性同步肿瘤更多、肿瘤侵犯更深结构。
- 免疫抑制组复杂闭合、未完成Mohs及更多手术切片更常见。
- 免疫抑制患者术中并发症发生率更高,但调整手术年份、抗血小板/抗凝治疗或闭合类型等变量后差异不再显著。
- 免疫抑制患者复发率显著高于免疫正常患者(IRR 2.79)。
关键数值与推荐
- 免疫抑制患者相比免疫正常患者的复发率比值比为2.79(IRR 2.79)。
临床怎么用
- 对免疫抑制患者行Mohs显微描记手术时,应关注其更高的不良事件和复发风险。
- 免疫抑制患者术后需密切随访,并考虑其非黑素瘤皮肤癌的特殊特征。
局限性
- 需要延长随访的进一步研究以更好理解该患者群体的长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunosuppressed (IS) patients, particularly solid organ transplant recipients and those on immunosuppressive therapy, face a higher incidence and recurrence of nonmelanoma skin cancers (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Mohs micrographic surgery (MMS) is the preferred treatment for high-risk NMSC due to its high cure rate and margin examination capabilities. However, IS patients may experience more complications, such as surgical site infections, and a greater risk of recurrence, making their outcomes a subject of interest. OBJECTIVES: This study aimed to compare IS and immunocompetent (IC) patients undergoing MMS for NMSC in terms of baseline characteristics, intra- and post-surgical complications, and postoperative recurrence rates. METHODS: The study utilized data from the REGESMOHS registry, a 7-year prospective cohort study in Spain. It included 5226 patients, categorizing them into IC (5069) and IS (157) groups. IS patients included solid organ transplant recipients, those on immunosuppressive treatments, individuals with haematological tumours and HIV-positive patients. Patient data, tumour characteristics, surgical details and outcomes were collected and analysed. RESULTS: IS patients demonstrated a higher proportion of SCC, multiple synchronous tumours and tumours invading deeper structures. Complex closures, unfinished MMS and more surgical sections were observed in the IS group. Although intra-operative morbidity was higher among IS patients, this difference became non-significant when adjusted for other variables such as year of surgery, antiplatelet/anticoagulant treatment or type of closure. Importantly, IS patients had a substantially higher recurrence rate (IRR 2.79) compared to IC patients. CONCLUSIONS: This study suggests that IS patients may be at a higher risk of development of AE such as bleeding or tumour necrosis and are at a higher risk of tumour recurrence. Close follow-up and consideration of the specific characteristics of NMSC in IS patients are crucial. Further research with extended follow-up is needed to better understand the long-term outcomes for this patient group.
引用
- Abril-Pérez C, Mansilla-Polo M, Escutia-Muñoz B, et al. Mohs micrographic surgery in immunosuppressed vs immunocompetent patients: Results of a prospective nationwide cohort study (REGESMOHS, Spanish registry of Mohs surgery). J Eur Acad Dermatol Venereol. 2024. PMID: 38733285. doi:10.1111/jdv.20103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。